NCT03274661View on ClinicalTrials.gov

Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

November 3, 2017

Primary Completion Date

October 20, 2020

Study Completion Date

March 19, 2022

Conditions
Solid Tumor, Adult
Interventions
DRUG

Pembrolizumab 200 mg Q3W

Pembrolizumab 200 mg Intravenous Infusion every 3 weeks administered on Day 1 of each 3 week cycle

Trial Locations (1)

33176

Miami Cancer Institute at Baptist Health, Inc., Miami

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Miami Cancer Institute

OTHER

lead

Baptist Health South Florida

OTHER

NCT03274661 - Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors | Biotech Hunter | Biotech Hunter